Treatment of prostate cancer cells with fisetin suppresses mTOR activity and downregulates the subunits Raptor, Rictor, PRAS40 and GβL, in addition to activating the mTOR repressor tuberous sclerosis complex 2 (TSC2). The gene discussed is MTOR; the disease is prostate cancer.